Rhodes Jennifer J
Known title: EVP, CHIEF LEGAL OFFICER, SECCIK: 0001568249
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target. Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.
Transaction History
| ACAD | ▼ Sell | Open Market | 3,844 | $83K | 3/25/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 7,515 | $0 | 3/24/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 6,950 | $162K | 2/9/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 12,944 | $0 | 2/6/2026 | View on chart |
| ELTX | ▼ Sell | Open Market | 451 | $1K | 12/14/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 433 | $2K | 11/15/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 430 | $4K | 10/14/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 430 | $5K | 9/14/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 445 | $5K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.